Infantile Spasms with Tuberous Sclerosis: What to Do When Vigabatrin Has Not Worked

This protocol addresses infants with infantile spasms occurring in the setting of tuberous sclerosis who have received first-line vigabatrin but did not achieve the expected treatment targets within the response window.

Clinical context — tuberous sclerosis

Tuberous sclerosis is an identified etiology that influences both treatment selection and expected response. Vigabatrin is the preferred first-line choice in this population, and initial therapy should be optimised before escalating; however, a structured next step exists when vigabatrin does not produce the required outcome.

Previous treatment — failure condition

First-line vigabatrin was initiated but did not achieve complete cessation of spasms or resolution of hypsarrhythmia on video EEG within 14 days. This protocol defines the structured response to that outcome.

Next-step approach (partial overview)

After vigabatrin failure in infantile spasms with tuberous sclerosis, switching to an alternative first-line medication — a hormonal therapy — is the structured next step. The specific agent, regimen, and follow-up algorithm are available in the full protocol.

Treatment goals

Complete cessation of spasms and resolution of hypsarrhythmia on video EEG, typically assessed within 14 days of initiating the new therapy.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.3978/j.issn.2224-4336.2015.09.01

Vigabatrin is the preferred first-line therapy for patients with infantile spasms and tuberous sclerosis, with some studies showing efficacy of greater than 90% in patients with tuberous sclerosis.
For example, patients with tuberous sclerosis are more likely to respond to treatment with vigabatrin, whereas patients without an identified etiology may respond better to hormonal therapy.
It is recommended to try two first-line therapies before moving on to other options, as there is less data to support the second-line treatments.
Studies have reported patients that respond to ACTH after failing corticosteroids and vice-versa.
The goals of therapy should include a complete cessation of the clinical events and resolution of hypsarrhythmia or modified hypsarrhythmia on video EEG.
Response is typically seen within 14 days or sooner.

View source ↗